




PHARMACEUTICAL 2023

Kintara Therapeutics Inc.
Rank 319 of 446





PHARMACEUTICAL 2023

Kintara Therapeutics Inc.
Rank 319 of 446

The relative strengths and weaknesses of Kintara Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Kintara Therapeutics Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Kintara Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 130% points.

The company's Economic Capital Ratio, given in the ranking table, is -24%, being 67% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	13,258
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,990
Liabilities, Non-Current	0
Other Assets	2,600
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	163
Other Net Income	21
Other Revenues	0
Property and Equipment	90
Research and Development	15,173
Selling, General and Administrative Expense	7,509

Output Variable	Value in 1000 USD
Assets	15,948
Liabilities	4,153
Expenses	22,682
Revenues	0
Stockholders Equity	11,795
Net Income	-22,661
Comprehensive Net Income	-22,661
Economic Capital Ratio	-24%